Business
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bol
About this update from Kyverna Therapeutics, Inc.
[{"type":"image","alt":"Kyverna Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kyverna Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/6f9f28e393a47bcb20d3d0e1f187b2f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NgRte8yTQVY2_NCia6rH2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6f9f28e393a47bcb20d3d0e1f187b2f0","width":300,"height":120}},"lazy":false},{"type":"text","content":"Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 ","length":182,"tagName":"p"},{"type":"text","content":" First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG)","length":93,"tagName":"p"},{"type":"text","content":"Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial","length":139,"tagName":"p"},{"type":"text","content":"Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bolstering Company’s CAR T commercialization experience; Ian Clark, former Chairperson, to remain on Board","length":186,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, provided today a corporate update and outlined its strategic priorities for 2026.","length":306,"tagName":"p"},{"type":"text","content":"“Our strong execution in 2025 solidifies our leadership position in autoimmune CAR T with unprecedented clinical trial results for miv-cel, positioning us to be first-to-market with a valuable commercial opportunity in stiff person syndrome, followed by myasthenia gravis,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “Looking ahead, we remain focused on preparing for our BLA filing with a clear regulatory path forward and the potential near-term launch in SPS, while executing on our Phase 3 gMG trial. These priorities are underpinned by our strong financial position, which will enable us to achieve key ...